Jeffrey Silva, Director of Product Development, Adeptrix Corporation discusses BAMS™ Assay Platform

Posted by

Bruker Mass Spectrometry

Jeffrey explained how BAMS™ Assay Platform simplifies the process for targeted- and discovery-based proteomic applications, by replacing the need for liquidchromatography separation methods in the analysis of complex biological samples by utilizing affinity enrichment (e.g. antibody-based) directed to specific target proteins, prior to MS analysis.